BeiGene
2025.04.30
13:34
Chinese stocks listed in Hong Kong strengthened in the afternoon, with Kingsoft Cloud (03896.HK) rising more than 13%, BeiGene (06160.HK) rising more than 7%, GDS (09698.HK) rising more than 6%, Baozun E-Commerce (09991.HK) and BOSS Direct (02076.HK) rising more than 2%.
13:17
The concept of innovative drugs in A-shares continued to strengthen. BeiGene, InnoCare Pharma, and Jinbo Biopharma all set historical highs. Kelun Pharmaceuticals, Ingenics, Zejing Pharmaceuticals, Huadong Medicine, and Hengrui Medicine were among the top gainers.
13:13
Innovative drug concepts continue to be active, and many stocks such as BeiGene hit record highs
The concept of innovative drugs continued to be active. BeiGene, InnoCare Pharma, and Jinbo Biopharma all hit record highs. Kelun Pharmaceuticals, Ingenics, Zejing Pharmaceuticals, Huadong Medicine, and Hengrui Medicine were among the top gainers.
13:04
BeiGene-U rose more than 6%, and the Science and Technology Innovation Pharmaceutical Index ETF (588700) held 7.05% of the stock
BeiGene-U's share price increased by 6.19%. The Science and Technology Innovation Pharmaceutical Index ETF (588700) holds 7.05% of the stock. The current share price increased by 1.78%, and it has risen for three consecutive days. The transaction volume was 14.811 million yuan. The share price decreased by 32.21% in the past month, a decrease of 122 million shares.
11:12
Most Hong Kong-listed biotech stocks strengthened, with CanSino Biologics (06185.HK) rising more than 10%, BeiGene (06160.HK) rising more than 6%, InnoCare Pharma (09969.HK) rising more than 4%, and Tiger Pharmaceuticals (03347.HK) rising more than 3%.
09:40
Hong Kong stocks' innovative drug sector rose in early trading, with BeiGene rising more than 6%
The Hong Kong stock market's innovative drug sector rose in early trading, with BeiGene rising more than 6%, Shijiazhuang Pharmaceutical Group and Rongchang Biopharma rising more than 3%, and Tiger Pharmaceuticals, Baiyunshan Pharmaceutical and Junshi Biopharma following suit.
2025.04.29
09:51
The Hong Kong stock market's innovative drug sector rose in early trading, with Tailing Pharmaceutical (01011.HK) rising nearly 7%, Shijiazhuang Pharmaceutical Group (01093.HK) rising more than 4%, BeiGene (06160.HK), Zhaoyan Pharmaceutical (06127.HK), and WuXi Biologics (02269.HK) all rising.
09:49
Hong Kong stocks' innovative drug sector rose in early trading, with Tailing Pharmaceutical rising nearly 7%
The Hong Kong stock market's innovative drug sector rose in early trading, with Tailing Pharmaceutical rising nearly 7%, Shijiazhuang Pharmaceutical Group rising more than 4%, BeiGene, Zhaoyan Pharmaceutical, and WuXi Biologics all rising.
2025.04.22
13:48
The A-share pharmaceutical sector continued to rise in the afternoon, and innovative drugs continued to lead the gains. Zhongsheng Pharmaceutical, Watson Pharmaceuticals, and Fujilife hit their daily limit, while Baili Tianheng, InnoCare Pharma, Sinopharm, and BeiGene hit historical highs. Fudan Zhangjiang, Shanghai YiZhong, Salidome, and Regeneron Biopharma were among the top gainers.
13:35
Hong Kong stocks' innovative drug sector continued to strengthen in the afternoon, with Innovent Biologics rising by more than 10%
The Hong Kong stock market's innovative drug sector continued to strengthen in the afternoon, with Innovent Biologics and Innovent Biologics rising by more than 10%, BeiGene rising by nearly 10%, and CSPC Pharmaceutical Group, Rongchang Biopharma, and WuXi Biologics all rising sharply.
09:51
The Hong Kong stock market's innovative drug sector strengthened, with Ascletis Pharmaceuticals (01672.HK) rising more than 20%, Rongchang Biopharma (09995.HK) and CSPC Pharmaceutical Group (01093.HK) rising more than 6%, and BeiGene (06160.HK) and Innovent Biologics (01801.HK) following suit.
09:44
Hong Kong stocks' innovative drug sector surged in early trading, with Ascletis Pharmaceuticals-B up more than 20%
The Hong Kong stock market's innovative drug sector surged in early trading, with Ascletis Pharmaceuticals-B rising more than 20%, Rongchang Biopharma and CSPC Pharmaceutical Group rising more than 6%, BeiGene and Innovent Biologics rising more than 3%.
2025.04.15
15:34
The Hong Kong stock market's biopharmaceutical sector continued to weaken, with Tiger Pharmaceuticals (03347.HK) falling more than 4%, BeiGene (06160.HK) falling more than 2%, and WuXi AppTec (02359.HK) and others following suit.
2025.04.14
09:45
The Hong Kong stock market's biopharmaceutical sector strengthened in early trading, with Zai Lab (09688.HK) rising more than 12%, Junshi Biosciences (01877.HK) rising more than 5%, and BeiGene (06160.HK), WuXi AppTec (02359.HK) and others following suit.
2025.04.11
14:17
A-share innovative drug concepts fluctuated and rose. Hisun Pharmaceuticals hit the daily limit in the afternoon, and its share price hit a historical high. Ipomoea rose more than 10%. Many stocks including Sinovac Biotech, Sunshine Novo, BioAtla, BeiGene, and Hansen Pharmaceutical rose by more than 5%.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Apple (AAPL.O): Vietnam is expected to be the country of origin for most iPads, Macs, Apple Watches and Airpods sold in the United States.

2025-05-02

US judge rules Apple violated order to reform App Store

2025-05-01

Shanghai: Using tax support to encourage more innovation and help companies go global

2025-04-30

Ideal Auto's Ring OS is officially open source, and the code is now available for download

2025-04-28

Apple (AAPL.O) had a net profit of US$24.78 billion in the second quarter of fiscal year 2025, compared with market expectations of US$24.26 billion and US$23.636 billion in the same period last year.

2025-05-02

ASIA TECH WIRE

Grasp technology trends

Download